Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS Trial

NCT05205512 | Completed DMC

• 3 other identifiers: 21595NCI-2021-13305P30CA033572
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

This clinical trial tests how well a telehealth exercise intervention works to improve cardiovascular health in lymphoma survivors. Telehealth exercise is a service to help perform physical exercises at home with a care provider online. With the use of telehealth exercise lymphoma survivors may be able to participate in exercise programs safely to improve heart health and reduce the risk of cardiovascular disease.

Conditions

Hodgkin Lymphoma; Non-Hodgkin Lymphoma

Outcome Measures

Primary Outcomes (1)

• Adherence to the telehealth exercise intervention

  Adherence will be measured by the number of exercise sessions attended over the exercise sessions prescribed (17/24 sessions).

  Up to 2 years

Secondary Outcomes (1)

• Effects of an 8-week telehealth exercise intervention

  At baseline up to week 9

Study Arms (2)

Group I (telehealth exercise)

EXPERIMENTAL

Patients participate in telehealth exercise intervention for 30 minutes per day, 3 days a week for 8 weeks.

Other: Questionnaire Administration; Other: Telemedicine

Group II (delayed control)

ACTIVE COMPARATOR

Patients maintain current levels of physical activity for 8 weeks. Patients may then participate in telehealth exercise intervention for 8 weeks.

Other: Exercise Intervention; Other: Questionnaire Administration; Other: Telemedicine

Interventions

Exercise Intervention OTHER

Maintain current levels of physical activity

Group II (delayed control)

Questionnaire Administration OTHER

Ancillary studies

Group I (telehealth exercise); Group II (delayed control)

Telemedicine OTHER

Participate in telehealth exercise intervention

Also known as: Telehealth

Group I (telehealth exercise); Group II (delayed control)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosed with Hodgkin or non-Hodgkin lymphoma.
• \>= 18 years old.
• Are between 2-5 years after completing anti-cancer therapy and with no evidence of disease.
• Intermediate (4-5) to high ( \>= 6) risk of cardiovascular risk factors based on six key variables: Age 30 to 50 years (y) \[2\]) and \>= 50y \[3\]; anthracycline dose \>250mg/m \^ 2 \[1\]; hypertension \[2\]; diabetes \[2\]; smoking \[1\]; and chest radiation \[1\]).
• Able to understand and sign the informed consent document.
• Physically able and willing to complete all study procedures.

You may not qualify if:

• Have overt cardiovascular disease within 6 months (e.g. myocardial infarction, stroke, angina).
• Have contraindications to exercise.
• Participate in structured exercise (\>60 minutes/week).
• Female patients who are pregnant or planning to become pregnant.

Sponsors & Collaborators

• City of Hope Medical Center: lead
• National Cancer Institute (NCI): collaborator

Study Sites (1)

City of Hope Medical Center

Duarte, California, 91010, United States

Location

MeSH Terms

Conditions

Hodgkin Disease; Lymphoma, Non-Hodgkin

Interventions

Telemedicine

Condition Hierarchy (Ancestors)

Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Intervention Hierarchy (Ancestors)

Delivery of Health Care; Patient Care Management; Health Services Administration

Study Officials

• Kyuwan Lee

  City of Hope Medical Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 27, 2021
• First Posted: January 25, 2022
• Study Start: September 14, 2022
• Primary Completion: June 9, 2025
• Study Completion: June 9, 2025
• Last Updated: October 6, 2025

Record last verified: 2025-10

Locations

US (1)